Form 4: Crinetics Pharmaceuticals Director Receives Equity Grants Valued at Over 17,000 Shares and Options

Crinetics Pharmaceuticals, Inc. Director Stephanie Okey was granted 6,900 restricted stock units and 10,350 stock options as part of her compensation, aligning her interests with shareholders.

Summary

• Stephanie Okey, a Director of Crinetics Pharmaceuticals, Inc. (CRNX), reported changes in her beneficial ownership of company securities.
• On June 11, 2025, Ms. Okey acquired 6,900 shares of Common Stock in the form of restricted stock units (RSUs) at a price of $0 per share.
• These RSUs are set to vest 100% on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders, contingent on her continued service on the board.
• Following this transaction, Ms. Okey beneficially owns 16,300 shares of Common Stock.
• Additionally, on June 11, 2025, Ms. Okey acquired 10,350 stock options with an exercise price of $32.33 per share.
• These stock options also vest on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders, subject to her continued board service, and expire on June 11, 2035.
• After this transaction, Ms. Okey beneficially owns 10,350 stock options.

Sentiment

Score: 7

Explanation: The sentiment is positive as the equity grants align the director's interests with shareholders, which is generally viewed favorably for corporate governance and long-term value creation.

Positives

• The equity grants to Director Stephanie Okey align her financial interests directly with the long-term performance of Crinetics Pharmaceuticals, Inc. and its shareholders.
• The grants are a standard form of compensation for non-employee directors, indicating a routine and expected corporate governance practice.

Future Outlook

The restricted stock units and stock options are subject to vesting conditions, requiring continued service on the board of directors until the earlier of the first anniversary of the grant date or the next annual meeting of stockholders.

Industry Context

This Form 4 filing reflects a routine equity compensation grant to a director, a common practice in the biotechnology and pharmaceutical industries to incentivize long-term commitment and align leadership interests with shareholder value creation.

Comparison to Industry Standards

• Equity grants, such as restricted stock units and stock options, are a common form of compensation for non-employee directors across publicly traded companies, particularly in the biotechnology and pharmaceutical sectors like Crinetics Pharmaceuticals, Inc.
• This practice aligns the interests of directors with those of shareholders by tying a portion of their compensation to the company's stock performance.

Corporate Governance

Related Party Transactions

• The transaction involves the issuance of equity compensation (restricted stock units and stock options) by Crinetics Pharmaceuticals, Inc. to Stephanie Okey, a director of the company, which constitutes a related party transaction.

Stakeholder Impact

• Shareholders: The grants align the director's incentives with shareholder interests, potentially leading to more focused efforts on long-term company performance.
• Employees: No direct impact on employees mentioned in this filing.

Next Steps

• The restricted stock units and stock options will vest on the earlier of the first anniversary of the grant date (June 11, 2026) or the next annual meeting of the Issuer's stockholders, subject to continued service.

Key Dates

Keywords

Crinetics Pharmaceuticals, CRNX, Form 4, Insider Transaction, Restricted Stock Units, Stock Options, Director Compensation, Equity Grant, Beneficial Ownership